Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatme... ( LAWRENCEVILLE Ga. and CARDIFF Wales J...)

Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product

Date:6/16/2011

LAWRENCEVILLE, Ga. and CARDIFF, Wales, June 16, 2011 /PRNewswire/ -- Genesis Biosciences, a global leader in custom fermentation, microbial product formulation and antimicrobial product development, announced today that it received the Pulire Innovation Award in the chemical products category for its e card sanitary bin sanitizer. This prestigious award, which honors creative products, solutions and entrepreneurial ideas in the professional cleaning and environmental hygiene field, was presented to Genesis during the Pulire Exhibition in Verona last month. Genesis' e card is the latest addition to its Biosan series of products for treatment of sanitary waste.

(Logo: http://photos.prnewswire.com/prnh/20110615/MM20879LOGO)

"As a first-time attendee of Pulire, our team is honored to be recognized by industry experts for our cutting-edge technology and innovative approach to the research and development instrumental in the creation of effective antimicrobial products for professional cleaning," stated Conrad Mielcuszny, president and chief executive officer of Genesis Biosciences. "At Genesis Biosciences, we are committed to constantly evolving and improving our technology to bring value to our customers, and this award represents the first of many accomplishments and achievements that our team expects to make this year."

The Pulire Exhibition, a globally respected industry event, is an international trade exhibition for professional cleaning technologies. The Pulire Innovation Award was open to the nearly 300 exhibitors participating in three categories: chemical products, machines and equipment. Three products for each nomination category were short-listed prior to the start of the trade show. These products, showcased by some of the top industry leaders, were characterized by progressive technologies and advanced know-how, and offered improved performance with r
'/>"/>

SOURCE Genesis Biosciences
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
2. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
3. ThermoGenesis Announces China Customer Implements Cord Blood Products
4. Tissue Genesis Begins FDA-Approved Clinical Trial
5. CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
6. Organogenesis, Life Sciences Center Break Ground on Worlds Largest Automated Living Cell Manufacturing Plant
7. Announcing ValGenesis On-Demand SaaS Solution
8. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
9. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
10. Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform
11. Genesis Biopharma Appoints L. Stephen Coles M.D., Ph.D. to Board of Directors

Post Your Comments:

(Date:6/18/2013)... Clara, CA (PRWEB) June 18, 2013 ... to standard size SEMs but have limited performance and ... lower resolution. Full size SEMs would normally provide better ... more knowledge to operate and have a higher cost ... address the gap between these two types of ...

(Date:6/18/2013)... 17, 2013) A million electric cars could be on ... with the help of research by the United States Department ... Waterloo. , Professor Zhongwei Chen is part of a team ... non-precious materials to replace the expensive platinum catalysts in fuel ... of fuel cells in vehicles is the cost of the ...

(Date:6/18/2013)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing, ... unaudited financial results for the fourth quarter and full ... Fourth Quarter of Fiscal 2013 Highlights ... 2013 increased by 33.3% to RMB133.0 million ($21.4 million) ...

(Date:6/18/2013)... In support of Swiss contributions to ... of Switzerland in New York is pleased to welcome ... PlanetSolar , to Manhattan. PlanetSolar is in New ... tour with scientists on board from the University of ... exclusively on energy from the sun and eliminates the ...

[0] Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes [0] US and Canadian researchers drive towards cheaper fuel cells for electric cars [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City

... Inc.,(NASDAQ: ISOT ) ("IsoTis"), an orthobiologics company, today ... it called to approve,the acquisition of IsoTis by Integra ... an agreement and plan of merger,dated as of August ... held at 9 a.m. Pacific time,today. An insufficient number ...

... Oct. 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... for 2007 after the market closes on Tuesday, November ... 4:30 p.m. EST,1:30 p.m. PST, on the company,s website. ... to the Company,s website at, http://www.cvt.com and go ...

... to be initiated by end of 2007 -, ... BIIB ) and PDL BioPharma, Inc. (PDL) (Nasdaq: ... a significant reduction in new or,enlarged gadolinium-enhancing lesions when ... active relapsing multiple,sclerosis (MS). These data will be presented ...

Cached Biology Technology:IsoTis Adjourns Special Meeting to October 23, 2007 2 IsoTis Adjourns Special Meeting to October 23, 2007 3 IsoTis Adjourns Special Meeting to October 23, 2007 4 CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6

IsoTis Adjourns Special Meeting to October 23, 2007 CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy

(Date:6/18/2013)... , June 19, 2013 Paris Air Show ... Geotest-Marvin Test Systems) , a leading provider of ... industries, is demonstrating its solutions this week at ... 3-C82. With growing challenges including increasingly complex armament ... efficient, feature-rich, specialized aerospace test solutions that address ...

(Date:6/18/2013)... at the University of Calgary,s Faculty of Medicine have ... body from harmful bacteria. Platelets, a component of blood ... for specific bacteria, and upon detection, seal it off ... were published in Nature Immunology this week, ... immunity. , "The science community has known that platelets ...

(Date:6/18/2013)... Researchers from the United Kingdom, the Energy Department,s ... of Kentucky have recently published a paper describing ... borer Limnoria quadripunctata , commonly known as ... because they exhibit a relatively unique ability to ... microbes to break down the biomass they eat. ...

Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2 Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3 Immunity mechanism discovered 2 Novel enzyme from tiny gribble could prove a boon for biofuels research 2

[0] Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show [0] Immunity mechanism discovered [0] Novel enzyme from tiny gribble could prove a boon for biofuels research

... the growing demand from the public and the scientific ... Press has revised its copyright policy to allow authors ... three journals. The policy, which became effective May 1, ... Journal of Cell Biology, The Journal of Experimental Medicine ...

... the human genome has been sequenced, research into mechanism of ... most human genes have not been isolated. This is true ... protein kinases, which mediate the majority of signaling events in ... It has been estimated by systematic gene sequencing efforts that ...

... which he calls a "smarthroscope", may be able to ... could be useful in developing countries. It aims ... the tissue surrounding an area affected by illnesses such ... and bone damage. The instrument would also help ...

Cached Biology News:Rockefeller University Press allows authors to retain copyright to their published work 2 QUT researchers develop smart instrument for tissue damage assessment 2

Rockefeller University Press allows authors to retain copyright to their published work Researchers report the cloning of a key group of human genes, the protein kinases QUT researchers develop smart instrument for tissue damage assessment

... extends the legendary MSn performance of the ... information through Thermo Scientifics innovations in ion ... is the only mass spectrometer that offers ... Pulsed Q Collision Induced Dissociation (PQD) ...

... The reliable and compact GC-8A is ... applications. Economical and simple to use, the ... or flow control, on column injection port(s), ... ramp program models are available. The GC-8A ...

... system combines world-class performance hardware, Cerity Networked ... world-renowned support and columns, as well as ... that lets you reach uncompromising results and ... data. The Agilent 6820 GC system is ...

... new chapter to a 40-year ... 7890A GC gives you everything ... lab to the next level ... including advanced separation capabilities, powerful ...

Biology Products:

LTQ XL with ETD from Thermo Scientific GC-8 Gas Chromatograph from Shimadzu 6820 GC from Agilent Technologies 7890A GC from Agilent Technologies